SCHEMBL2290505

SCHEMBL2290505

COC(=O)c1ccccc1NC(=O)c1ccc(COc2ccc(Br)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.67
▸ HPGD P15428 3/20 0.67
▸ ALDH1A1 P00352 2/20 0.67
▸ MAPT P10636 2/20 0.67
▸ RAB9A P51151 4/20 0.58
▸ TSHR P16473 3/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ ELANE P08246 1/20 0.58
▸ PRTN3 P24158 1/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ SENP7 Q9BQF6 2/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ TAAR1 Q96RJ0 1/20 0.57
▸ SENP8 Q96LD8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291513 0.90 KDM4E (0.69) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL22445033 0.88 TSHR (0.74) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL2294814 0.87 SENP7 (0.74) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL2291128 0.87 KDM4E (0.66) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL6338190 0.87 KDM4E (0.66) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL2291530 0.83 KDM4E (0.69) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL9337435 0.81 TSHR (0.68) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL13719210 0.81 TSHR (0.72) KDM4EHPGDALDH1A1MAPTTSHR
SCHEMBL2292344 0.81 KDM4E (0.74) KDM4EHPGDALDH1A1MAPTRAB9A
SCHEMBL2295551 0.81 NPC1 (0.71) KDM4EHPGDALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 — — US claimed
JP-2008546661-A — — 2008-12-25 — — JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 — — EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 — — WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 — — US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 — — US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 — — US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 — — EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 — — WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 KDM4E 3357/4885HPGD 922/4885ALDH1A1 529/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 KDM4E 3132/4885HPGD 1058/4885ALDH1A1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback